Staging and prognosis of colon cancer

Josh Kehoe, Vijay P. Khatri

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Significant advances have been made in all aspects of care relating to colorectal cancer. Although surgery will likely remain the mainstay of definitive treatment for the majority of colorectal malignancies, a better understanding of tumor progression and biology will help guide the choice of surgical therapy to best achieve a curative resection. Additionally, advances in the use of neoadjuvant and adjuvant therapies should continue to increase disease-free and overall survival when combined with appropriate operative resection. Although TNM staging remains our strongest tool at this point for establishing prognosis and directing therapy, expansion of our knowledge of the molecular events underlying colorectal tumorigenesis undoubtedly will lead to the refinement of our current staging and prognostic systems.

Original languageEnglish (US)
Pages (from-to)129-146
Number of pages18
JournalSurgical Oncology Clinics of North America
Volume15
Issue number1
DOIs
StatePublished - Jan 2006

Fingerprint

Colonic Neoplasms
Neoadjuvant Therapy
Neoplasm Staging
Disease-Free Survival
Colorectal Neoplasms
Neoplasms
Carcinogenesis
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Surgery

Cite this

Staging and prognosis of colon cancer. / Kehoe, Josh; Khatri, Vijay P.

In: Surgical Oncology Clinics of North America, Vol. 15, No. 1, 01.2006, p. 129-146.

Research output: Contribution to journalArticle

Kehoe, Josh ; Khatri, Vijay P. / Staging and prognosis of colon cancer. In: Surgical Oncology Clinics of North America. 2006 ; Vol. 15, No. 1. pp. 129-146.
@article{a15ffb7e1c944045b4978907852943ea,
title = "Staging and prognosis of colon cancer",
abstract = "Significant advances have been made in all aspects of care relating to colorectal cancer. Although surgery will likely remain the mainstay of definitive treatment for the majority of colorectal malignancies, a better understanding of tumor progression and biology will help guide the choice of surgical therapy to best achieve a curative resection. Additionally, advances in the use of neoadjuvant and adjuvant therapies should continue to increase disease-free and overall survival when combined with appropriate operative resection. Although TNM staging remains our strongest tool at this point for establishing prognosis and directing therapy, expansion of our knowledge of the molecular events underlying colorectal tumorigenesis undoubtedly will lead to the refinement of our current staging and prognostic systems.",
author = "Josh Kehoe and Khatri, {Vijay P.}",
year = "2006",
month = "1",
doi = "10.1016/j.soc.2005.08.006",
language = "English (US)",
volume = "15",
pages = "129--146",
journal = "Surgical Oncology Clinics of North America",
issn = "1055-3207",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Staging and prognosis of colon cancer

AU - Kehoe, Josh

AU - Khatri, Vijay P.

PY - 2006/1

Y1 - 2006/1

N2 - Significant advances have been made in all aspects of care relating to colorectal cancer. Although surgery will likely remain the mainstay of definitive treatment for the majority of colorectal malignancies, a better understanding of tumor progression and biology will help guide the choice of surgical therapy to best achieve a curative resection. Additionally, advances in the use of neoadjuvant and adjuvant therapies should continue to increase disease-free and overall survival when combined with appropriate operative resection. Although TNM staging remains our strongest tool at this point for establishing prognosis and directing therapy, expansion of our knowledge of the molecular events underlying colorectal tumorigenesis undoubtedly will lead to the refinement of our current staging and prognostic systems.

AB - Significant advances have been made in all aspects of care relating to colorectal cancer. Although surgery will likely remain the mainstay of definitive treatment for the majority of colorectal malignancies, a better understanding of tumor progression and biology will help guide the choice of surgical therapy to best achieve a curative resection. Additionally, advances in the use of neoadjuvant and adjuvant therapies should continue to increase disease-free and overall survival when combined with appropriate operative resection. Although TNM staging remains our strongest tool at this point for establishing prognosis and directing therapy, expansion of our knowledge of the molecular events underlying colorectal tumorigenesis undoubtedly will lead to the refinement of our current staging and prognostic systems.

UR - http://www.scopus.com/inward/record.url?scp=29444461589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29444461589&partnerID=8YFLogxK

U2 - 10.1016/j.soc.2005.08.006

DO - 10.1016/j.soc.2005.08.006

M3 - Article

C2 - 16389154

AN - SCOPUS:29444461589

VL - 15

SP - 129

EP - 146

JO - Surgical Oncology Clinics of North America

JF - Surgical Oncology Clinics of North America

SN - 1055-3207

IS - 1

ER -